Rifabutin-associated hypopyon uveitis in human immunodeficiency virus–negative immunocompetent individuals

O’Brien, 1990, Rifabutin (Ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex, Am Rev Respir Dis, 141, 821, 10.1164/ajrccm/141.4_Pt_1.821 Nightingale, 1993, Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS, N Engl J Med, 329, 828, 10.1056/NEJM199309163291202 Shafran, 1994, Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network, N Engl J Med, 330, 438, 10.1056/NEJM199402103300616 Griffith, 1995, Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease, Clin Infect Dis, 21, 594, 10.1093/clinids/21.3.594 Moorthy, 1998, Drug induced uveitis, Surv Ophthalmol, 42, 557, 10.1016/S0039-6257(97)00130-6 Jewelewicz, 1998, Rifabutin-associated uveitis in an immunosuppressed pediatric patient without acquired immunodeficiency syndrome, Am J Ophthalmol, 125, 872, 10.1016/S0002-9394(98)00056-7 Saran, 1994, Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin, Arch Ophthalmol, 112, 1159, 10.1001/archopht.1994.01090210043015 Prince, 1989, Infection with Mycobacterium avium complex in patients without predisposing conditions, N Engl J Med, 321, 863, 10.1056/NEJM198909283211304 Iseman MD. Mycobacterium avium complex and the normal host: the other side of the coin [editorial]. N Engl J Med 1989;321:896–8. Comment on: N Engl J Med 1989;321:863–8.